ACP
RCKT icon

Acuta Capital Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Acuta Capital Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-83,350
Closed -$556K – 35
2025
Q1 		$556K Sell
83,350
-51,150
-38% -$505K 0.64% 29
2024
Q4 		$1.69M Sell
134,500
-55,500
-29% -$835K 1.7% 19
2024
Q3 		$3.51M Sell
190,000
-60,370
-24% -$1.24M 2.84% 14
2024
Q2 		$5.39M Sell
250,370
-76,417
-23% -$1.76M 4.54% 7
2024
Q1 		$8.8M Sell
326,787
-39,228
-11% -$1.11M 5.72% 5
2023
Q4 		$11M Buy
366,015
+4,015
+1% +$88.6K 6.17% 3
2023
Q3 		$7.42M Buy
362,000
+55,806
+18% +$1.01M 4.97% 7
2023
Q2 		$6.08M Buy
306,194
+8,194
+3% +$166K 4.12% 8
2023
Q1 		$5.1M Buy
298,000
+38,000
+15% +$744K 3.76% 10
2022
Q4 		$5.09M Buy
+260,000
New +$4.79M 3.13% 16
2021
Q1 		– Sell
-20,000
Closed -$1.1M – 55
2020
Q4 		$1.1M Buy
+20,000
New +$729K 0.3% 43
2018
Q2 		– Sell
-350,000
Closed -$6.56M – 70
2018
Q1 		$6.56M Buy
+350,000
New +$5.71M 1.07% 21

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Acuta Capital Partners's RCKT Position: Q2 2025 in Review

Acuta Capital Partners sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 83,350 shares — an estimated $556K sold.

Acuta Capital Partners first reported a position in RCKT in Q1 2018 and held it in 12 quarters. The position peaked at $11M in Q4 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Acuta Capital Partners reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 83,350 Rocket Pharmaceuticals shares in Q2 2025, an estimated $556K.
  • Acuta Capital Partners first reported a position in Rocket Pharmaceuticals in Q1 2018 and held it in 12 quarters.
  • Acuta Capital Partners's Rocket Pharmaceuticals position peaked at $11M in Q4 2023.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Acuta Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.